Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Accured Expenses for 4 consecutive years, with -$689000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 82.02% to -$689000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $5.4 million, a 167.89% increase, with the full-year FY2024 number at $22.8 million, up 2957.09% from a year prior.
  • Change in Accured Expenses was -$689000.0 for Q3 2025 at Centessa Pharmaceuticals, down from $2.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $32.7 million in Q4 2024 to a low of -$29.6 million in Q1 2025.
  • A 4-year average of $58466.7 and a median of $2.0 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 1501.47% in 2024; the steepest drop was 2706.12% in 2024.
  • Centessa Pharmaceuticals' Change in Accured Expenses stood at -$4.8 million in 2022, then soared by 142.28% to $2.0 million in 2023, then surged by 1501.47% to $32.7 million in 2024, then crashed by 102.1% to -$689000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Accured Expenses are -$689000.0 (Q3 2025), $2.9 million (Q2 2025), and -$29.6 million (Q1 2025).